Crooke Rosanne M
Isis Pharmaceuticals, Inc., 1896 Rutherford Avenue, Carlsbad, CA 92008, USA.
Expert Opin Biol Ther. 2005 Jul;5(7):907-17. doi: 10.1517/14712598.5.7.907.
Hyperlipidaemia, due to elevations of low-density lipoprotein cholesterol (LDL-C) or triglycerides (TGs), is recognised as a significant risk factor contributing to the development of coronary heart disease (CHD), the leading cause of morbidity and mortality in the Western world. Even though a variety of established antihyperlipidaemic agents are available, the majority of high-risk patients do not reach their lipid goals, indicating the need for new and more effective therapeutics to be used alone or as combination agents with existing drugs. Antisense oligonucleotides (ASOs), designed to specifically and selectively inhibit novel targets involved in cholesterol/TG homeostasis, represent a new class of agents that may prove beneficial for the treatment of hyperlipidaemias resulting from various genetic, metabolic or behavioural factors. This article describes the antisense technology platform, highlights the advantages of these novel drugs for the treatment of hyperlipidaemia and reviews the current research in this area.
由于低密度脂蛋白胆固醇（LDL-C）或甘油三酯（TGs）升高引起的高脂血症，被认为是导致冠心病（CHD）发生的重要危险因素，而冠心病是西方世界发病和死亡的主要原因。尽管有多种已确立的抗高脂血症药物可用，但大多数高危患者并未达到其血脂目标，这表明需要新的、更有效的治疗方法单独使用或与现有药物联合使用。反义寡核苷酸（ASOs）旨在特异性和选择性地抑制参与胆固醇/TG稳态的新靶点，代表了一类新的药物，可能被证明对治疗由各种遗传、代谢或行为因素引起的高脂血症有益。本文描述了反义技术平台，强调了这些新型药物治疗高脂血症的优势，并综述了该领域的当前研究。
